Comparative cost savings of biosimilar and dose rounding utilization in oncology care.

ABSTRACT:

Introduction

The exponential rise in cancer costs has led many centers to utilize dose rounding to the nearest vial size when the difference in dose is ≤10% to decrease costs. The recent approval of several biosimilar products has presented another opportunity to mitigate the rising costs of oncology care. Scarce information exists about the expected cost savings of combining dose rounding strategies (DRS) with biosimilar use (BU). We therefore assessed the cost savings of combining DRS and BU.

Methods

Electronic health record data for two health systems in Rhode Island were used to identify patients who received ≥1 of trastuzumab, trastuzumab-anns, bevacizumab, or bevacizumab-awwb from October 1, 2015 to September 1, 2020. Costs were estimated using Medicare drug pricing. M

SUBMITTER: Abdelmeseh V 

PROVIDER: S-EPMC10113396 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature